With a market cap of $32.6 billion, San Diego, California-based ResMed Inc. (RMD) is a global leader in designing, ...

Resmed (RMD) announced the publication of a meta-analysis in The Lancet Respiratory Medicine, demonstrating that CPAP therapy significantly ...

(RTTNews) - Resmed Inc (RMD) Wednesday said it has published a meta analysis in The Lancet Respiratory Medicine showing that CPAP therapy significantly reduces the risk of death for people with ...

“For people with OSA, using CPAP versus not using CPAP can literally be a matter of life or death,” said Carlos Nunez, M.D., Resmed’s Chief Medical Officer. “Decades of research have shown CPAP can ...

Resmed (NYSE: RMD) announced today that it began a comprehensive brand evolution to unify its brand portfolio.

ResMed showed 29% EPS growth last quarter. Sales gains came in at 10%. ResMed earns the No. 6 rank among its peers in the ...

ResMed has launched a rebrand to unify its portfolio and reflect its increasing direct-to-consumer engagement.

The company has launched initiatives including a consumer campaign for CPAP therapy and a physician education campaign to facilitate earlier diagnosis. By 2030, Resmed aims to empower 500 million ...

Shares of ResMed Inc. RMD shed 2.00% to $220.25 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 1.07% to 5,614.66 and ...

CPAP therapy significantly reduces the risk of death for people with obstructive sleep apnea, according to a landmark meta-analysis supported by Resmed and published in The Lancet Respiratory Medicine ...

The study, led by global experts in sleep and respiratory medicine and supported by Resmed, found that people with OSA who use CPAP therapy have: A 37% lower risk of dying from any cause compared ...

Largest ever meta-analysis on the long-term benefits of CPAP therapy, published in The Lancet Respiratory Medicine, found that in people with sleep apnea, CPAP therapy lowered the overall chance of dy ...